Reid, I., Miller, P., Brown, J., Fraser, W., Hosking, D., Devogelaer, J. P., … Lyles, K. (2006). A single dose of zoledronic acid 5mg achieves more sustained biochemical remission versus daily 30mg risedronate in patients with Paget's disease. In OSTEOPOROSIS INTERNATIONAL (Vol. 17, pp. S31–S31). Harrogate, ENGLAND: SPRINGER LONDON LTD.

Reid, I., P. Miller, J. Brown, W. Fraser, D. Hosking, J. P. Devogelaer, C. Moniz, et al. “A single dose of zoledronic acid 5mg achieves more sustained biochemical remission versus daily 30mg risedronate in patients with Paget's disease.” In OSTEOPOROSIS INTERNATIONAL, 17:S31–S31. SPRINGER LONDON LTD, 2006.

Reid I, Miller P, Brown J, Fraser W, Hosking D, Devogelaer JP, et al. A single dose of zoledronic acid 5mg achieves more sustained biochemical remission versus daily 30mg risedronate in patients with Paget's disease. In: OSTEOPOROSIS INTERNATIONAL. SPRINGER LONDON LTD; 2006. p. S31–S31.

Reid, I., et al. “A single dose of zoledronic acid 5mg achieves more sustained biochemical remission versus daily 30mg risedronate in patients with Paget's disease.” OSTEOPOROSIS INTERNATIONAL, vol. 17, SPRINGER LONDON LTD, 2006, pp. S31–S31.

Reid I, Miller P, Brown J, Fraser W, Hosking D, Devogelaer JP, Moniz C, Hooper M, Saidi Y, Su G, Pak J, Davis J, Fashola T, Krasnow J, Zelenakas K, Lyles K. A single dose of zoledronic acid 5mg achieves more sustained biochemical remission versus daily 30mg risedronate in patients with Paget's disease. OSTEOPOROSIS INTERNATIONAL. SPRINGER LONDON LTD; 2006. p. S31–S31.